Regranion
- Company typePrivate
- Founded2009
- HeadquartersMount Pleasant, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Regranion does
Regranion, LLC is a clinical-stage biopharmaceutical company developing RGRN-305, an orally delivered small molecule inhibitor of heat shock protein 90 (HSP90), for the treatment of autoimmune skin diseases. Founded in 2009 and headquartered in Mount Pleasant, United States, the company operates with a small team of 1-10 employees and is pre-revenue. Its lead asset targets hyperinflammation in moderate to severe plaque psoriasis and hidradenitis suppurativa (HS), with a mechanism of action designed to downregulate multiple inflammatory mediators simultaneously rather than inhibiting a single cytokine or chemokine.
RGRN-305 has demonstrated clinical safety and efficacy in both psoriasis and hidradenitis suppurativa trials, with no specific organ toxicity concerns and no consistent changes in hematology or biochemistry parameters reported in the available data. The product's pharmacological differentiation rests on broad-spectrum anti-inflammatory activity through HSP90 inhibition, an approach positioned by the company as addressing unmet clinical need in moderate to severe disease where single-target biologics have limitations.
The business model is a traditional pharmaceutical product sales model contingent on regulatory approval. The anticipated go-to-market is enterprise field sales targeting dermatologists, hospital systems, and specialty pharmacy channels, with distribution expected to flow through standard pharmaceutical wholesalers and specialty pharmacy networks upon commercialization. No pricing, partnerships, or capital structure details are disclosed in the source material.
Regranion firmographics
Firmographics- Name
- Regranion
- Legal name
- Regranion, LLC
- Website
- https://regranion.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Regranion industry classification
Industry- Product category
- Dermatology Pharmaceuticals
- akta.pro primary industry
- Acne & Rosacea Specialty Care (HLAKACAH)
Keywords
Where Regranion is headquartered
LocationHeadquarters
- HQ city
- Mount Pleasant
- HQ country
- United States
- HQ region
- North America
Markets served
Regranion business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Revenue: Pre-revenue clinical-stage biopharmaceutical company. Revenue expected upon regulatory approval and commercialization of RGRN-305 for psoriasis and hidradenitis suppurativa. Revenue model would be traditional pharmaceutical product sales through prescription channels.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Regranion product offering
Product offeringCore offering
Regranion is a clinical-stage biopharmaceutical company developing RGRN-305, an orally delivered small molecule inhibitor of heat shock protein 90 (HSP90) for the treatment of autoimmune skin diseases. The lead product targets hyperinflammation in moderate to severe plaque psoriasis and hidradenitis suppurativa through broad-spectrum anti-inflammatory activity, modulating multiple inflammatory mediators simultaneously rather than individual cytokines or chemokines.
Product overview
Regranion is a clinical-stage biopharmaceutical company with a single lead product, RGRN-305. RGRN-305 is an orally delivered potent small molecule HSP90 inhibitor that functions as a broad-spectrum anti-inflammatory molecule, targeting multiple inflammatory mediators of autoimmune skin diseases rather than individual cytokines or chemokines. The product is in clinical development for hidradenitis suppurativa and plaque psoriasis, demonstrating clinical safety and efficacy without specific organ toxicity concerns.
Differentiator
Problem solved
Functional benefit
Products and services
- RGRN-305
Quantifiable outcome
- No specific organ toxicity concerns and no consistent changes in hematology or biochemistry parameters in clinical trials
- +1 more outcomes
Companies that use Regranion
Customer profileSegments1 record
Ideal customer profiles1 record
Regranion technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Regranion partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Regranion competitors and assessment
Company assessmentBroad incumbents
- Galderma: Dermatology-focused specialty pharma with products spanning acne, rosacea, and other inflammatory skin conditions. Indirectly comparable as a dermatology-specialized competitor with overlapping physician channels.
- Bristol-Myers Squibb: Markets Sotyktu (deucravacitinib), a first-in-class oral TYK2 inhibitor for psoriasis. Highly relevant comparator as the leading oral systemic that RGRN-305 would compete against on convenience and label breadth.
- Novartis: Markets Cosentyx (secukinumab), a leading IL-17 inhibitor for psoriasis and HS. Directly competes with Regranion's target indications and represents a major class competitor.
- UCB: Develops and commercializes Bimzelx for psoriasis, psoriatic arthritis, and HS. Comparable as a direct therapeutic competitor targeting Regranion's lead indications.
- Johnson & Johnson (Janssen): Markets Stelara and Tremfya for psoriasis and HS. Comparable as a leading IL-12/23 and IL-23 inhibitor in Regranion's target patient populations.
- Amgen: Markets Otezla (apremilast), an oral PDE4 inhibitor approved for psoriasis and other indications. Directly comparable as an oral systemic competitor to RGRN-305 in plaque psoriasis.
- AbbVie: Global biopharmaceutical leader with Humira, Skyrizi, and Rinvoq spanning psoriasis and HS. Sets the commercial, pricing, and access bar that any new autoimmune skin entrant like Regranion must compete against.
- Eli Lilly: Markets Taltz (ixekizumab) for psoriasis and psoriatic arthritis. Comparable as a major IL-17 competitor in Regranion's target plaque psoriasis market.
Direct peers
- Moonlake Immunotherapeutics: Clinical-stage biotech with lead asset sonelokinab in hidradenitis suppurativa. Closely comparable to Regranion in stage (clinical), therapeutic focus on HS, single-asset profile, and small-cap biotech characteristics.
- Arcutis Biotherapeutics: Late clinical-stage dermatology company with approved and pipeline products in inflammatory skin diseases including psoriasis. Comparable in clinical-stage dermatology specialty focus and small-cap biotech profile to Regranion.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Regranion social profiles
Digital presenceRegranion financial estimates
Financial estimateRevenue estimate
Valuation estimate
Regranion leadership team
Management profileNumber of profiles
Profiles1 record
Regranion funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Regranion M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Regranion
What does Regranion do?
Regranion is a clinical-stage biopharmaceutical company developing RGRN-305, an orally delivered small molecule inhibitor of heat shock protein 90 (HSP90) for the treatment of autoimmune skin diseases. The lead product targets hyperinflammation in moderate to severe plaque psoriasis and hidradenitis suppurativa through broad-spectrum anti-inflammatory activity, modulating multiple inflammatory mediators simultaneously rather than individual cytokines or chemokines.
Is Regranion a public or private company?
Regranion is a private company. It is classified as unknown and is currently operating.
When was Regranion founded?
Regranion was founded in 2009. It employs 1 to 10 people.
Where is Regranion based?
Regranion is headquartered in Mount Pleasant, United States, in the North America region.
How does Regranion make money?
One revenue line is on record: pharmaceutical Product Revenue.
Who are Regranion's main competitors?
Broad incumbents on record are Galderma, Bristol-Myers Squibb, Novartis, UCB, Johnson & Johnson (Janssen), Amgen, AbbVie and Eli Lilly. Direct peers are Moonlake Immunotherapeutics and Arcutis Biotherapeutics.
Does Regranion have an API?
No public API is recorded for Regranion.
What industry is Regranion in?
Regranion's product category is Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAKACAH, Acne & Rosacea Specialty Care.